Skip to main content

Table 1 Iguratimod only has weak inhibition on COX-2 activity

From: Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

Celecoxib

Iguratimod

Concentration (M)

Inhibition (%)

Concentration (M)

Inhibition (%)

1.0 × 10−6

97.8

1.0 × 10−6

24.9

  

1.0 × 10−7

19.2

  

1.0 × 10−8

35.5

  

1.0 × 10−9

31.3

  1. The COX-2 inhibition activities of iguratimod or celecoxib was determined with cyclooxygenase products, prostaglandins, which were measured by EIA. At the same concentration (1.0 × 10−6 M), iguratimod exhibited weak inhibition on COX-2 inhibition activity(24.9%), obviously less than celecoxib (97.8%). One representative experiment out of three was shown
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us